Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers....

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Res Notes
Autori principali: Vallo, Stefan, Michaelis, Martin, Gust, Kilian M., Black, Peter C., Rothweiler, Florian, Kvasnicka, Hans-Michael, Blaheta, Roman A., Brandt, Maximilian P., Wezel, Felix, Haferkamp, Axel, Cinatl, Jindrich
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2016
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039786/
https://ncbi.nlm.nih.gov/pubmed/27677700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-016-2256-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi